Urinary tract infection+1
Not recruitingStudy of meropenem-vaborbactam safety and effectiveness in children aged 3 months to 12 years with complicated urinary tract infection or acute pyelonephritis
Study of meropenem-vaborbactam safety and effectiveness in children aged 3 months to 12 years with complicated urinary tract infection or acute pyelonephritis
- Disease:Urinary tract infectionPyelonephritis acute
- Substances:MeropenemVaborbactam
Bulgaria- Participants:0–17 years
- Substances:Meropenem
- Sponsor:Rempex Pharmaceuticals Inc.













